These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Newer developments in the treatment of Gram-positive infections. Koomanachai P; Crandon JL; Nicolau DP Expert Opin Pharmacother; 2009 Dec; 10(17):2829-43. PubMed ID: 19929705 [TBL] [Abstract][Full Text] [Related]
10. Daptomycin. Enoch DA; Bygott JM; Daly ML; Karas JA J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567 [TBL] [Abstract][Full Text] [Related]
11. Risk factors and management of Gram-positive bacteraemia. Cervera C; Almela M; Martínez-Martínez JA; Moreno A; Miró JM Int J Antimicrob Agents; 2009; 34 Suppl 4():S26-30. PubMed ID: 19931813 [TBL] [Abstract][Full Text] [Related]
12. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson A Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Mohr JF; Friedrich LV; Yankelev S; Lamp KC Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
15. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384 [TBL] [Abstract][Full Text] [Related]
17. [Microbiologic study of bacteremia and fungemia in chronic hemodialysis patients]. Zárate MS; Jordá Vargas L; Lanza A; Relloso S; Díaz C; Smayevsky J Rev Argent Microbiol; 2005; 37(3):145-9. PubMed ID: 16323664 [TBL] [Abstract][Full Text] [Related]
18. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. Ashour HM; el-Sharif A J Clin Oncol; 2007 Dec; 25(36):5763-9. PubMed ID: 18089873 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]